Navigation Links
Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
Date:7/9/2013

NEW YORK, July 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals Inc. (OTCQB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the Actinium Pharmaceuticals' clinical programs and platform technology were presented in Vienna, Austria, at a technical meeting at the International Atomic Energy Agency (IAEA). The presentation was delivered by Dr. David Scheinberg, Interim Director of the Sloan-Kettering Institute, research division of the Memorial Sloan-Kettering Cancer Center.

"There is increasing interest in the uses of alpha particle therapy around the world," said Dr. Scheinberg. "We now see scientists, clinicians, isotope manufacturers, government agencies and commercial companies collaborating to enable therapeutic advances of these agents against cancer." 

Dr. Scheinberg's presentation focused on Actinium Pharmaceuticals' drug candidates Actimab-A and Bismab for acute myeloid leukemia as well as applications of alpha immunotherapy in treatment of solid cancers. The IAEA meeting at the United Nations headquarters in Vienna, Austria, was a closed workshop entitled "Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy".

About Actimab - A
Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium-225 and bismuth-213.  Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells. Actimab-A consists of the Lintuzumab monoclonal antibody and actinium-225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first developed by Dr. David Scheinberg at Memorial Sloan-Kettering Cancer Center.

About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:
Visit our web site www.actiniumpharmaceuticals.com or

Contact:
Segio Traversa, CEO
Actinium Pharmaceuticals Inc.
E-mail: straversa@actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
E-mail: dsdobson@optonline.com  
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
2. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
3. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
4. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
5. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
6. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
7. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
8. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
9. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
10. Actinium Pharmaceuticals Announces New Round of Financing
11. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...   Seno Medical Instruments, Inc. , the leader ... the development of an opto-acoustic (OA/US) imaging device, today ... SVP of Engineering. Mr. Miller previously served as the ... headquarters in Bothell, Washington . Mr. ... to the development of innovative medical imaging products that ...
(Date:1/18/2017)... 2017  Tarix Orphan LLC today announced that the ... Pediatric Disease (RPD) designation for the company,s drug candidate ... (RDEB), a rare genetic skin disorder. There are currently ... to supportive care. "The RPD designation for ... granted by the FDA in this indication," said ...
(Date:1/18/2017)... YORK , January 18, 2017 ... of people regarding the use of cannabis both for medical ... only are more Americans open to the use of cannabis, ... financial sectors. According to Arcview Market Research, the North American ... up 30% from the previous year. The research projects sales ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... 2017 , ... Floundering on New Year’s resolutions? Need an excuse to get ... reset. The U.S. Apple Association agrees and recommends starting each day with apples, ... to heart disease. , The U.S. Apple Association – which represents apple growers and ...
(Date:1/17/2017)... ... January 17, 2017 , ... In the crowded Ath-leisure market, ... stand-out company for several differences from other mainstream brands. , Firstly, in ... is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows them to have ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SunView Software’s ... Award for Innovation of the Year. , Each year, Pink Elephant recognizes ... an innovative approach to address a specific business problem or opportunity. The award highlights ...
(Date:1/17/2017)... Clemente, CA (PRWEB) , ... January 17, 2017 ... ... Diego County, as well as Palm Desert, is opening a new office in ... Brainsway deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling ...
(Date:1/17/2017)... New York (PRWEB) , ... January 17, 2017 ... ... network – SightMD – will lecture to primary eye care practitioners on the ... conditions at the upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, ...
Breaking Medicine News(10 mins):